Cart
sales@molnova.com
TG-2-IN-1
CAS No. 135273-74-4
TG-2-IN-1( —— )
Catalog No. M35396 CAS No. 135273-74-4
TG-2-IN-1 is a potent transglutaminase-2 (TGM-2) inhibitor.TG-2-IN-1 is used in the study of cancer, neurological disorders, and immune system disorders.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 62 | Get Quote |
|
| 5MG | 85 | Get Quote |
|
| 10MG | 122 | Get Quote |
|
| 25MG | 195 | Get Quote |
|
| 50MG | 287 | Get Quote |
|
| 100MG | 417 | Get Quote |
|
| 500MG | 963 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameTG-2-IN-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionTG-2-IN-1 is a potent transglutaminase-2 (TGM-2) inhibitor.TG-2-IN-1 is used in the study of cancer, neurological disorders, and immune system disorders.
-
DescriptionTG-2-IN-1 is a potent transglutaminase-2 (TGM-2) inhibitor.TG-2-IN-1 is used in the study of cancer, neurological disorders, and immune system disorders.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number135273-74-4
-
Formula Weight220.72
-
Molecular FormulaC8H13ClN2OS
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES[Cl-].O=C(C)CSC=1N(C=C[N+]1C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Leucosceptoside A
Leucosceptoside A shows inhibitory activity against PKCalpha with the IC50 value of 19.0 microM; it also exhibits strong inhibitory capacity against α-glucosidase.
-
Benzidine orange
Benzidine orange shows mutagenic and carcinogenic activity.
-
Oxindole
Oxindole is an aromatic heterocyclic building block.?2-indolinone derivatives have become lead compounds in the research of kinase inhibitors.Oxindole structure has been used in receptor tyrosine kinases (RTKs) inhibitors such as SU4984 and intedanib, the RTK family represents an important therapeutic target for anti-cancer drug development.
